antibodies

Datasheet for ABIN4995964 anti-SMPD1 antibody (AA 201-300) (AbBy Fluor® 680)



Overview

Quantity:	100 µL
Target:	SMPD1
Binding Specificity:	AA 201-300
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This SMPD1 antibody is conjugated to AbBy Fluor® 680
Application:	Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human Acid sphingomyelinase	
lsotype:	lgG	
Cross-Reactivity:	Human, Mouse, Rat	
Predicted Reactivity:	Dog,Cow,Pig,Rabbit	
Purification:	Purified by Protein A.	
Target Details		
Target:	SMPD1	
Alternative Name:	Acid sphingomyelinase (SMPD1 Products)	

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/3 | Product datasheet for ABIN4995964 | 06/08/2024 | Copyright antibodies-online. All rights reserved.

phosphodiesterase 1 acid lysosomal. Sphingomyelin phosphodiesterase. Background: Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1.2 diacytglycerolphosphocholine and 1.2 diacytglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity. Involvement in disease: Defects in SMPD1 are the cause o Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantlie form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and ther metabolically related lipids in reticuloendothelial and other cell types throughout the body. leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurosisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediativpes encompass a cluster of variants combining clinical features of both types A and B. Gene ID 6609 UniProt. P17405 Application Notes: IF(IHC-P) 1:50:200 IF(IHC-P) 1:50:200 IF(IHC-F) 1:50:200 IF(IHC-F) 1:50:200 IF(IHC-F) 1:50:200 IF(ICC) 1:50:200 IF(IHC-F) 1:50:200 IF(IHC-F) 1:50:200 IF(IHC-F) 1:50:200 IF(IHC-F) 1:50:200 IF(IHC-F) 1:50:200	Background:	Supprime: Acid enhingemyolingen ASM ACM HUMAN SCHees NDD Smodt Schingsmuslin
Background: Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1.2 diacy[glycerolphosphocholine and 1.2 diacy[glycerolphosphoglycerol. Isoform 2 and isoform 3 have lost oatalytic activity.thvolvement in disease: Defects in SMPD1 are the cause o Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorders. failure to thrive, major hepatospilenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details For Research Use only Handling For Research Use only Handling Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TES (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.	Баскугоции.	
1.2-diacy[g]ycero]phosphocholine and 1.2-diacy[g]ycero]phosphog]ycerol. Isoform 2 and isoform 3 have lost catalytic activity. Involvement in disease: Defects in SMPD1 are the cause on Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body. leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder; characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic Application Details F(HC-P) 1:50-200 Application Notes: IF(IHC-P) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Handling Format: Iquid Concentration: 1 µg/µl. Buffer: Aqueou		
isoform 3 have lost atalytic activity involvement in disease: Defects in SMPD1 are the cause on Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder: characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediati types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(HC-P) 1:50-200 IF(IC-P) 1:50-200 IF(IC-P) 1:50-200 IF(IC-C) 1:50-200 IF(IC-C) 1:50-200 IF(IC-C) 1:50-200 IF(IC-C) 1:50-200 Handling For Research Use only Handling Iugud Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.		
Niemann-Pick disease type A (NPDA), also known as Niemann-Pick disease classical infantile form. It is an early-onset typosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Notes: IF(IHC-P) 1:50-200 IF(CC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 </th <th></th> <th></th>		
form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticulcendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Olinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200		
sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticulcendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorders, failure characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC -F) 1:50-200 IF(IHC -F) 1:50-200 IF(IHC -F) 1:50-200 IF(
metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(HC-P) 1:50-200 IF(HC-F) 1:50-200 IF(HC-F) 1:50-200 IF(HC		
leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(IC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Buffer: Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.011M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300		
characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IC) 1:50-200 IF(IHC-P) 1:50-200 IF(IT) Experimental experimontexperimental experimontexperimental experim		
to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details Application Notes: IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(IHC-F) 1:50-200 IF(IRC F) 1:50-200 IF(IHC F) 1:50-200 IF(IRC F) 1:50-200 IF(IHC F) 1:50-200 IF(IRC F) 1:50-200 IF(IRC F) 1:50-200 IF(IRC F) 1:50-200 IF(IRC F) 1:50-200 IF(IRC F) 1:50-200 IF(IRC F) 1:50-200 Handling IF(IRC F) 1:50-200 Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin </td <td></td> <td></td>		
neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Buffer: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		
four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC -F) 1:50-200 IF(IHC -F) 1:50-200 <		
neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details F(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Eiquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		
types encompass a cluster of variants combining clinical features of both types A and B. Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Bartinet For Research Use only Handling If(ICC) 1:50-200 Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		
Gene ID: 6609 UniProt: P17405 Application Details IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iuiquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		
UniProt: P17405 Application Details Application Notes: IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		types encompass a cluster of variants combining clinical features of both types A and B.
Application Details Application Notes: IF(IHC-P) 1:50-200 IF(ICC) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iuiuid Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Gene ID:	6609
Application Notes: IF(IHC-P) 1:50-200 IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Iiquid Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	UniProt:	P17405
IF IF(IHC-F) 1:50-200 IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Application Details	
IF(ICC) 1:50-200 Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Application Notes:	IF(IHC-P) 1:50-200
Restrictions: For Research Use only Handling Liquid Format: Liquid Concentration: 1 µg/µL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		IF(IHC-F) 1:50-200
Handling Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin		IF(ICC) 1:50-200
Format: Liquid Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Restrictions:	For Research Use only
Concentration: 1 μg/μL Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Handling	
Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. Preservative: ProClin	Format:	Liquid
50 % Glycerol. Preservative: ProClin	Concentration:	1 μg/μL
	Buffer:	
Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be	Preservative:	ProClin
	Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 2/3 | Product datasheet for ABIN4995964 | 06/08/2024 | Copyright antibodies-online. All rights reserved.

lond	lina
land	

	handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months